German cannabis grower Demecan has launched FE 800 No.1, the country's first fresh cannabis extract made using the Live Rosin process, now available through Germany's regulated medical supply chain. While this method has already made a name for itself in North America as a premium alternative, this marks a market first for Europe, the company shares.
Produced exclusively from fresh, flash-frozen plant material and extracted purely through mechanical processes – without the use of chemical solvents like butane, ethanol, or CO₂ – they preserve the plant's full profile of active ingredients. The result is a creamy, high-potency extract containing over 90% active compounds, including cannabinoids and terpenes. Demecan manufactures this extract in Germany under pharmaceutical GMP conditions, setting a new quality benchmark in the sector.
© Demecan
"This product allows us to introduce an innovative, globally proven format into Germany's medical cannabis system – safe, effective, and pharmaceutical-grade," says Dr. Adrian Fischer, CEO of DEMECAN. "As the first and only manufacturer producing a Live Rosin fresh extract under GMP conditions in Germany, we are setting new standards for therapeutic cannabis extracts. We're not only improving supply security for patients, but also reinforcing Germany's role as a hub for medical cannabis innovation and research."
The launch comes at a time of rapid growth in the German market. Germany is now the largest medical cannabis market in Europe – and the second largest globally. According to current forecasts by Prohibition Partners and Germany's Federal Institute for Drugs and Medical Devices (BfArM), the market is currently valued at around €420 million, with projections pointing to a rise beyond €1 billion by 2028.
Medical cannabis imports have more than doubled year over year – from 32.5 tonnes in 2023 to over 72 tonnes in 2024 – a clear indicator of rising demand and growing patient access.
"This launch proves that we are leading the German medical cannabis market with innovation," adds Fischer. "Not only does this product deliver real therapeutic value to patients, it also shows how international quality standards can be combined with German precision and regulatory reliability."
For more information:
Demecan
[email protected]
www.demecan.de
